A retrospective multicenter study assessing safety and efficacy of teriflunomide in relapsing-remitting multiple sclerosis patients
Latest Information Update: 30 Oct 2018
Price :
$35 *
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 30 Oct 2018 New trial record
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis